|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.15 HKD | -2.47% |
|
-6.48% | +6.58% |
| 01-02 | JD Health Surges Amid China's Healthcare Boom | |
| 12-22 | China Merchants Securities (Hong Kong) Starts JD Health International at Buy | MT |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | 0.99 | -1.91 | -0.17 | 0.63 | 1.07 | |||
Return on Total Capital | 1.12 | -2.21 | -0.21 | 0.83 | 1.38 | |||
Return On Equity % | -88.86 | -2.71 | 0.91 | 4.55 | 7.95 | |||
Return on Common Equity | -88.86 | -2.71 | 0.9 | 4.55 | 7.96 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 25.37 | 23.46 | 21.16 | 22.17 | 22.88 | |||
SG&A Margin | 20.08 | 25 | 18.98 | 18.57 | 18.05 | |||
EBITDA Margin % | 2.21 | -4.47 | -0.13 | 1.48 | 2.26 | |||
EBITA Margin % | 2.14 | -4.58 | -0.31 | 1.41 | 2.2 | |||
EBIT Margin % | 2.14 | -4.58 | -0.31 | 1.18 | 2 | |||
Income From Continuing Operations Margin % | -88.92 | -3.5 | 0.82 | 4 | 7.15 | |||
Net Income Margin % | -88.92 | -3.5 | 0.81 | 4 | 7.16 | |||
Net Avail. For Common Margin % | -88.92 | -3.5 | 0.81 | 4 | 7.16 | |||
Normalized Net Income Margin | 1.72 | -1.84 | 0.92 | 3.14 | 5.16 | |||
Levered Free Cash Flow Margin | 18.59 | 10.5 | 6.77 | 5.14 | 4.05 | |||
Unlevered Free Cash Flow Margin | 18.6 | 10.51 | 6.78 | 5.15 | 4.05 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.74 | 0.67 | 0.86 | 0.85 | 0.86 | |||
Fixed Assets Turnover | 295.46 | 163.3 | 182.32 | 198.29 | 107.31 | |||
Receivables Turnover (Average Receivables) | 27.45 | 70.82 | 54.76 | 53.32 | 74.34 | |||
Inventory Turnover (Average Inventory) | 9.61 | 9.84 | 8.15 | 7.52 | 8.21 | |||
Short Term Liquidity | ||||||||
Current Ratio | 9.12 | 5.71 | 3.45 | 3.28 | 3.77 | |||
Quick Ratio | 8.72 | 5.3 | 3.04 | 2.89 | 3.37 | |||
Operating Cash Flow to Current Liabilities | 0.79 | 0.43 | 0.36 | 0.32 | 0.28 | |||
Days Sales Outstanding (Average Receivables) | 13.33 | 5.15 | 6.66 | 6.85 | 4.92 | |||
Days Outstanding Inventory (Average Inventory) | 38.09 | 37.1 | 44.76 | 48.54 | 44.58 | |||
Average Days Payable Outstanding | 41.02 | 63.38 | 77.28 | 100.68 | 95.59 | |||
Cash Conversion Cycle (Average Days) | 10.4 | -21.13 | -25.85 | -45.3 | -46.08 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 0.23 | 0.5 | 0.45 | 0.43 | 0.47 | |||
Total Debt / Total Capital | 0.23 | 0.5 | 0.44 | 0.43 | 0.47 | |||
LT Debt/Equity | 0.16 | 0.34 | 0.29 | 0.24 | 0.27 | |||
Long-Term Debt / Total Capital | 0.16 | 0.33 | 0.29 | 0.24 | 0.27 | |||
Total Liabilities / Total Assets | 10.78 | 16.97 | 26.91 | 23.2 | 22.5 | |||
EBIT / Interest Expense | 121.56 | -234.05 | -15.95 | 66.51 | 141.92 | |||
EBITDA / Interest Expense | 129.53 | -223.52 | -0.49 | 90.49 | 168.12 | |||
(EBITDA - Capex) / Interest Expense | 124.94 | -307.23 | -4.9 | 84.04 | 163.41 | |||
Total Debt / EBITDA | 0.2 | -0.15 | -44.87 | 0.25 | 0.19 | |||
Net Debt / EBITDA | -90.88 | 31.17 | 10.68K | -47.78 | -37 | |||
Total Debt / (EBITDA - Capex) | 0.21 | -0.11 | -4.47 | 0.27 | 0.19 | |||
Net Debt / (EBITDA - Capex) | -94.23 | 22.67 | 1.06K | -51.44 | -38.07 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 78.77 | 58.3 | 52.32 | 14.54 | 8.65 | |||
Gross Profit, 1 Yr. Growth % | 74.85 | 46.37 | 37.43 | 19.95 | 12.16 | |||
EBITDA, 1 Yr. Growth % | -2 | -476.3 | -95.56 | -1.4K | 65.41 | |||
EBITA, 1 Yr. Growth % | -3.78 | -499.33 | -89.66 | -892.88 | 69.63 | |||
EBIT, 1 Yr. Growth % | -3.78 | -499.33 | -89.66 | -534.71 | 84.34 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 1.67K | -93.78 | -135.72 | 459.16 | 93.99 | |||
Net Income, 1 Yr. Growth % | 1.67K | -93.77 | -135.41 | 463.49 | 94.31 | |||
Normalized Net Income, 1 Yr. Growth % | 24.23 | -94.71 | -176.54 | 289.64 | 78.49 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | 1.63K | -95.56 | -134.29 | 466.67 | 94.12 | |||
Accounts Receivable, 1 Yr. Growth % | -51.55 | -11.97 | 220.72 | -45.68 | 21.39 | |||
Inventory, 1 Yr. Growth % | 35.52 | 75.55 | 97.16 | -15.2 | 14.91 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | 610.14 | 126.75 | -3.4 | 14.32 | 176.39 | |||
Total Assets, 1 Yr. Growth % | 407.04 | 9.11 | 27.66 | 4.91 | 10.87 | |||
Tangible Book Value, 1 Yr. Growth % | -8.63K | 1.54 | 6.74 | 10.96 | 12.64 | |||
Common Equity, 1 Yr. Growth % | -8.65K | 1.54 | 12.36 | 10.22 | 11.9 | |||
Cash From Operations, 1 Yr. Growth % | 803.48 | -7.26 | 72.13 | -22.02 | -5.92 | |||
Capital Expenditures, 1 Yr. Growth % | 202.72 | 3.1K | -92 | 52.35 | -36.91 | |||
Levered Free Cash Flow, 1 Yr. Growth % | 1.11K | -9.58 | -1.8 | -12.98 | -14.54 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | 1.02K | -9.52 | -1.73 | -12.95 | -14.53 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 54.04 | 68.22 | 55.28 | 32.09 | 11.55 | |||
Gross Profit, 2 Yr. CAGR % | 57.63 | 59.98 | 41.83 | 28.4 | 15.99 | |||
EBITDA, 2 Yr. CAGR % | 18.02 | 77.19 | -59.11 | -23.87 | 364.54 | |||
EBITA, 2 Yr. CAGR % | 17.12 | 80.37 | -35.75 | -26.64 | 266.74 | |||
EBIT, 2 Yr. CAGR % | 17.12 | 80.37 | -35.75 | -32.97 | 183.08 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 795.49 | 5.07 | -85.09 | 41.33 | 229.35 | |||
Net Income, 2 Yr. CAGR % | 795.47 | 5.1 | -85.15 | 41.25 | 230.9 | |||
Normalized Net Income, 2 Yr. CAGR % | 31.83 | 45.15 | -79.88 | 72.69 | 163.72 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | - | -12.41 | -87.6 | 39.39 | 231.66 | |||
Accounts Receivable, 2 Yr. CAGR % | 376.02 | -34.69 | 68.02 | 31.99 | -18.8 | |||
Inventory, 2 Yr. CAGR % | 24.63 | 54.24 | 86.04 | 29.3 | -1.29 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | 413.06 | 301.28 | 48 | 5.09 | 77.76 | |||
Total Assets, 2 Yr. CAGR % | 510.05 | 135.21 | 18.02 | 15.73 | 7.85 | |||
Tangible Book Value, 2 Yr. CAGR % | 624.88 | 830.87 | 4.11 | 8.83 | 11.8 | |||
Common Equity, 2 Yr. CAGR % | 623.8 | 831.78 | 6.81 | 11.28 | 11.06 | |||
Cash From Operations, 2 Yr. CAGR % | 344.51 | 189.46 | 26.34 | 15.85 | -14.35 | |||
Capital Expenditures, 2 Yr. CAGR % | 179.26 | 884.07 | 59.94 | -65.1 | -1.96 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | 383.08 | 228.35 | -5.77 | -7.56 | -13.76 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 383.08 | 216.98 | -5.71 | -7.51 | -13.75 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | 51.69 | 55.44 | 62.75 | 40.3 | 23.76 | |||
Gross Profit, 3 Yr. CAGR % | 52.72 | 53.78 | 52.08 | 34.13 | 22.74 | |||
EBITDA, 3 Yr. CAGR % | 18.33 | 64.63 | -48.14 | 29.68 | -1.4 | |||
EBITA, 3 Yr. CAGR % | 17.45 | 66.77 | -30.46 | 29.05 | -2.99 | |||
EBIT, 3 Yr. CAGR % | 17.45 | 66.77 | -30.46 | 21.51 | -6.09 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 358.74 | 70.9 | -26.67 | -50.09 | 57.07 | |||
Net Income, 3 Yr. CAGR % | 358.73 | 70.94 | -26.87 | -50.1 | 57.09 | |||
Normalized Net Income, 3 Yr. CAGR % | 27.63 | 43.38 | 17.26 | -45.98 | 74.6 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | -35.74 | -55.67 | 55.66 | |||
Accounts Receivable, 3 Yr. CAGR % | 428.33 | 171.2 | 11.01 | 15.32 | 28.36 | |||
Inventory, 3 Yr. CAGR % | 25.14 | 39.71 | 67.4 | 43.18 | 24.31 | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | 212.68 | 290.81 | 149.63 | 35.8 | 45.06 | |||
Total Assets, 3 Yr. CAGR % | 264.11 | 243.71 | 91.86 | 13.48 | 14.08 | |||
Tangible Book Value, 3 Yr. CAGR % | 290.85 | 276.47 | 352.24 | 6.35 | 10.09 | |||
Common Equity, 3 Yr. CAGR % | 289.82 | 276.08 | 360.34 | 7.94 | 11.49 | |||
Cash From Operations, 3 Yr. CAGR % | 367.89 | 163.64 | 143.41 | 7.57 | 8.09 | |||
Capital Expenditures, 3 Yr. CAGR % | 165.17 | 529.53 | 97.84 | 57.37 | -57.48 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | 175.32 | 119.58 | -8.24 | -9.94 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | 175.37 | 114.53 | -8.19 | -9.91 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 53.12 | 45.64 | 39.93 | |||
Gross Profit, 5 Yr. CAGR % | - | - | 48.27 | 43.08 | 36.46 | |||
EBITDA, 5 Yr. CAGR % | - | - | -25.1 | 20.93 | 24.65 | |||
EBITA, 5 Yr. CAGR % | - | - | -10.75 | 20.07 | 24.32 | |||
EBIT, 5 Yr. CAGR % | - | - | -10.75 | 15.82 | 21.93 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 16.51 | 58.4 | 33.73 | |||
Net Income, 5 Yr. CAGR % | - | - | 16.32 | 58.38 | 33.76 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 21.96 | 54.45 | 62.16 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | 23.9 | |||
Accounts Receivable, 5 Yr. CAGR % | - | - | 234.11 | 103.32 | -2.04 | |||
Inventory, 5 Yr. CAGR % | - | - | 46.65 | 35.45 | 35.52 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | 131.83 | 131.1 | 117.92 | |||
Total Assets, 5 Yr. CAGR % | - | - | 132.02 | 122.38 | 52.38 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | 130.25 | 129.16 | 158.58 | |||
Common Equity, 5 Yr. CAGR % | - | - | 132.25 | 131.07 | 160.66 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 177.14 | 89.74 | 60.29 | |||
Capital Expenditures, 5 Yr. CAGR % | - | - | 116.62 | 97.95 | 49.4 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 77.93 | 51.09 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 77.99 | 49.01 |
- Stock Market
- Equities
- 6618 Stock
- Financials JD Health International Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















